Xtx Topco LTD Altimmune, Inc. Transaction History

Xtx Topco LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$5.91 - $10.23 $84,973 - $147,086	14,378 New	14,378 $95,000
Q3 2023 Nov 13, 2023	BUY	$2.4 - $3.45 $491,995 - $707,243	204,998 New	204,998 $532,000
Q1 2023 May 12, 2023	BUY	$4.19 - $16.83 $89,125 - $357,990	21,271 New	21,271 $89,000
Q2 2022 Aug 15, 2022	SELL	$3.94 - $11.77 $77,480 - $231,457	-19,665 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$5.9 - $9.45 $28,898 - $46,286	4,898 Added 33.17%	19,665 $120,000
Q4 2021 Feb 11, 2022	BUY	$8.69 - $12.48 $128,325 - $184,292	14,767 New	14,767 $135,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.